Pfizer has announced a doubling of its revenue thanks to the coronavirus vaccine. The US pharmaceutical industry announced that its annual revenue increased from $ 41.7 billion in 2020 to $ 81.3 billion in 2021 (about $ 71 billion), largely thanks to the vaccine.
The US pharmaceutical giant, which sold $ 37 billion worth of vaccines last year and expects $ 32 billion in sales this year, says it has spent “billions of dollars” in the early stages of the pandemic to develop the vaccine.
However, the company’s assessment of value sales $ 32 billion this year was lower than analysts’ expectations for about $ 34 billion. Analysts expected $ 33.79 billion in sales from the vaccine and $ 22.88 billion from Paxlovid, according to Refinitiv.
The Pfizer vaccine, developed in collaboration with Germany’s BioNTech and based on mRNA technology, is used in more than 160 countries, including the United States.
Overall, Pfizer forecast sales for 2022 to reach $ 98 billion to $ 102 billion, also lower than the $ 105.48 billion estimate.
“2021 was a milestone year for Pfizer,” said CEO Albert Burla. “Our successes in the front line of the fight against Covid-19 have not only made a positive difference in the world, but I believe they have radically changed our company forever,” he said.
See all the news
news.sky.com
Follow Skai.gr on Google News
and be the first to know all the news
